





The Consequences of Disinformation about GLP-1 Products


A flood of disinformation about GLP-1s is fueling an “infodemic,” or deluge of information – some accurate, most deceptive, designed to mislead, confuse, and exploit – that spreads online at lightning speed and puts patient safety at risk. New research commissioned by the National Consumers League reveals how widespread the crisis really is. In a comprehensive survey of 1,500 women in the U.S. :




believe the **false claims** made in a fictional ad for a hypothetical compounded GLP-1 product



think compounded GLP-1s have **received FDA approval**



believe compounded GLP-1s are only on the market if **tested and proven safe**



believe that compounded GLP-1s have the **same active ingredient as FDA-approved GLP-1s**

None of these perceptions is true.



Both the FDA and consumers have roles to play in addressing this infodemic. We urge the FDA to enforce federal law and its longstanding safety-guided standards for compounded products now that GLP-1 products are no longer in shortage.



Consumers are encouraged to consult a trusted healthcare provider to ensure they have accurate information about their GLP-1 medications and visit www.weight-truth.org to report fake GLP-1s and learn more.